Alumis Inc. (ALMS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Alumis Inc. (ALMS) closed at USD 6.06 on 2026-10-14, a change of +26 % over the past year, with a market capitalization of USD 816.74M.

Alumis Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Alumis Inc. key figures

Previous close

USD 6.06 (2026-10-14)

1-year change

+26 %

Market cap

USD 816.74M

Enterprise value

USD 350.87M

P/E ratio (trailing)

-1.70

P/E ratio (forward)

-2.20

EPS (trailing)

-3.71

EPS (forward)

-2.87

PEG ratio

n/a

Price to book

1.79

Revenue growth

-37.7 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.11

Employees

237

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Alumis Inc.

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Alumis Inc. and compare it with other stocks.